Logo image of ALDX

ALDEYRA THERAPEUTICS INC (ALDX) Stock Fundamental Analysis

NASDAQ:ALDX - Nasdaq - US01438T1060 - Common Stock - Currency: USD

6.69  -0.03 (-0.45%)

After market: 6.8 +0.11 (+1.64%)

Fundamental Rating

2

ALDX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of ALDX is average, but there are quite some concerns on its profitability. ALDX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALDX had negative earnings in the past year.
In the past year ALDX has reported a negative cash flow from operations.
ALDX had negative earnings in each of the past 5 years.
ALDX had a negative operating cash flow in each of the past 5 years.
ALDX Yearly Net Income VS EBIT VS OCF VS FCFALDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

The Return On Assets of ALDX (-38.18%) is comparable to the rest of the industry.
The Return On Equity of ALDX (-52.64%) is better than 64.12% of its industry peers.
Industry RankSector Rank
ROA -38.18%
ROE -52.64%
ROIC N/A
ROA(3y)-28.1%
ROA(5y)-41.98%
ROE(3y)-33.5%
ROE(5y)-58.02%
ROIC(3y)N/A
ROIC(5y)N/A
ALDX Yearly ROA, ROE, ROICALDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

ALDX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDX Yearly Profit, Operating, Gross MarginsALDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

ALDX has more shares outstanding than it did 1 year ago.
ALDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ALDX is higher compared to a year ago.
ALDX Yearly Shares OutstandingALDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ALDX Yearly Total Debt VS Total AssetsALDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 1.86 indicates that ALDX is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 1.86, ALDX is doing good in the industry, outperforming 70.16% of the companies in the same industry.
ALDX has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.18, ALDX is not doing good in the industry: 70.16% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z 1.86
ROIC/WACCN/A
WACCN/A
ALDX Yearly LT Debt VS Equity VS FCFALDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

ALDX has a Current Ratio of 6.80. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
ALDX has a better Current ratio (6.80) than 66.25% of its industry peers.
ALDX has a Quick Ratio of 6.80. This indicates that ALDX is financially healthy and has no problem in meeting its short term obligations.
ALDX's Quick ratio of 6.80 is fine compared to the rest of the industry. ALDX outperforms 66.43% of its industry peers.
Industry RankSector Rank
Current Ratio 6.8
Quick Ratio 6.8
ALDX Yearly Current Assets VS Current LiabilitesALDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

ALDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.85%.
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALDX will show a very strong growth in Earnings Per Share. The EPS will grow by 33.74% on average per year.
Based on estimates for the next years, ALDX will show a very strong growth in Revenue. The Revenue will grow by 172.29% on average per year.
EPS Next Y-46.23%
EPS Next 2Y12.79%
EPS Next 3Y18.74%
EPS Next 5Y33.74%
Revenue Next Year-100%
Revenue Next 2Y747.33%
Revenue Next 3Y263.79%
Revenue Next 5Y172.29%

3.3 Evolution

ALDX Yearly Revenue VS EstimatesALDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M 150M 200M 250M
ALDX Yearly EPS VS EstimatesALDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDX Price Earnings VS Forward Price EarningsALDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDX Per share dataALDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALDX's earnings are expected to grow with 18.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.79%
EPS Next 3Y18.74%

More info and screens

0

5. Dividend

5.1 Amount

ALDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (2/21/2025, 8:00:49 PM)

After market: 6.8 +0.11 (+1.64%)

6.69

-0.03 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-05 2025-03-05/amc
Inst Owners47.72%
Inst Owner Change-94.86%
Ins Owners2.4%
Ins Owner Change0%
Market Cap398.39M
Analysts88.57
Price Target10.49 (56.8%)
Short Float %7.52%
Short Ratio9.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-46.44%
Min EPS beat(2)-93.66%
Max EPS beat(2)0.77%
EPS beat(4)2
Avg EPS beat(4)-18.22%
Min EPS beat(4)-93.66%
Max EPS beat(4)44.08%
EPS beat(8)6
Avg EPS beat(8)7.82%
EPS beat(12)10
Avg EPS beat(12)9.39%
EPS beat(16)11
Avg EPS beat(16)6.43%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.6%
EPS NY rev (1m)0%
EPS NY rev (3m)-36.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.68
P/tB 4.68
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0
BVpS1.43
TBVpS1.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.18%
ROE -52.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.1%
ROA(5y)-41.98%
ROE(3y)-33.5%
ROE(5y)-58.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.8
Quick Ratio 6.8
Altman-Z 1.86
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.85%
Cap/Depr(5y)4.31%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-78.57%
EPS Next Y-46.23%
EPS Next 2Y12.79%
EPS Next 3Y18.74%
EPS Next 5Y33.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y747.33%
Revenue Next 3Y263.79%
Revenue Next 5Y172.29%
EBIT growth 1Y1.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-39.51%
EBIT Next 3Y18.69%
EBIT Next 5YN/A
FCF growth 1Y46.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.19%
OCF growth 3YN/A
OCF growth 5YN/A